Media coverage about Bio-Rad Laboratories (NYSE:BIO) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.7579455356292 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Clinical Microbiology Market: 2017 Global Industry Size, Trends, Demand, Manufacturers, Regions and Business Analysis 2022 Forecast Report (medgadget.com)
- Life Science & Analytical Instruments Market by Type, Material, Size, Share, Revenue Analysis Predict to 2023 (empowerednews.net)
- Global Cell Counting Market Set to Surge Significantly During 2016 – 2024 (sbwire.com)
- GW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session (finance.yahoo.com)
- Bio-Rad Laboratories, Inc. (BIO) CFO Christine A. Tsingos Sells 4,980 Shares (americanbankingnews.com)
Several brokerages have issued reports on BIO. Deutsche Bank reaffirmed a “buy” rating and set a $255.00 target price on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $291.00 target price on the stock in a research note on Wednesday. TheStreet raised shares of Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research note on Monday, November 13th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $290.00 target price (up previously from $250.00) on shares of Bio-Rad Laboratories in a research note on Wednesday, November 29th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $277.75.
Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.54 by $0.37. Bio-Rad Laboratories had a return on equity of 3.44% and a net margin of 1.15%. The business had revenue of $535.00 million for the quarter, compared to analyst estimates of $507.99 million. During the same quarter in the previous year, the firm earned $0.62 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. equities research analysts expect that Bio-Rad Laboratories will post 2.68 earnings per share for the current fiscal year.
Bio-Rad Laboratories declared that its board has approved a stock repurchase program on Tuesday, November 28th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
In other news, EVP Giovanni Magni sold 2,400 shares of Bio-Rad Laboratories stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $253.01, for a total transaction of $607,224.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at approximately $2,340,595.51. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Christine A. Tsingos sold 4,980 shares of Bio-Rad Laboratories stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $249.40, for a total value of $1,242,012.00. Following the transaction, the chief financial officer now owns 7,283 shares in the company, valued at approximately $1,816,380.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,126 shares of company stock worth $2,309,426. Insiders own 28.29% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2017/12/17/bio-rad-laboratories-bio-receiving-somewhat-favorable-media-coverage-report-shows.html.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.